Merit Medical Systems, Inc. (NASDAQ: MMSI) completed a $140 million acquisition of View Point Medical, Inc., paying $90 million in cash at closing and two deferred payments of $25 million each. The deal expands Merit’s product portfolio into the vascular access and hemostasis market, adding View Point’s proprietary OneMark ultrasound‑enhanced technology to the company’s existing SCOUT platform.
The acquisition is strategically positioned to broaden Merit’s therapeutic oncology footprint, particularly in breast and soft‑tissue tumor localization. View Point’s OneMark system is projected to generate $2 million to $4 million in revenue for the remainder of 2026 and $14 million to $16 million for the full year 2027, while its 70% non‑GAAP gross margin will reinforce Merit’s focus on higher‑margin products.
Merit’s 2025 free cash flow of $216 million and a net leverage ratio of 1.6x demonstrate strong liquidity, with a current ratio of 4.34. The acquisition is expected to dilute 2026 EPS by $0.05 but become accretive in 2027. Management highlighted that the transaction aligns with Merit’s disciplined M&A strategy and will support the company’s 2026 guidance of 5‑7% constant‑currency revenue growth and 20.6‑21% operating margins.
"This acquisition expands Merit's portfolio of therapeutic oncology products dedicated to the accurate diagnosis and localization of breast and soft tissue tumors. View Point's unique ultrasound‑enhanced technology offers a highly innovative solution to localize more lesions at the time of biopsy – representing an estimated 1.3 million procedures annually in the United States alone. We look forward to discussing this acquisition in further detail on our first quarter investor conference call," said Martha G. Aronson, President and CEO of Merit Medical Systems.
Analysts have responded with mixed views. BTIG reiterated a buy rating, while Wells Fargo downgraded Merit to equal weight, citing uncertainty around the 2026 guidance. The market reaction reflects cautious sentiment amid the company’s near 52‑week low, but the acquisition is viewed as a strategic tailwind that strengthens Merit’s competitive position against larger med‑tech peers.
The transaction positions Merit to capture a larger share of the interventional oncology market, enhances its capital‑light, single‑use model, and supports long‑term growth prospects by adding high‑margin, high‑volume product lines to its portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.